. "Letter Report." Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report. Washington, DC: The National Academies Press, 2008.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report
TABLE 5 Summary of Outcomes of the Six IPTi-SP Trials Through 12 Months of Age
NOTES: NA = not provided; PE = protective efficacy. Incidence of episodes (malaria and hospitalizations) analyzed “with a negative binomial regression to account for potential clustering within individuals. Robust standard errors were used to account for intra-cluster correlation at the community level for the Navrongo trial.” Clinical malaria: history of fever with any P. falciparum parasitemia. Risk of anemia (at least one episode) was analyzed using a Poisson regression model with a log-link and a robust error variance. To assess the sensitivity of the results to any single study, the SWG analyzed each outcome omitting one trial at a time. Estimates rounded to the nearest whole percentage.
aLocally cut-offs:>500μ/l for Ifakara, Manhiça, and Kumasi; >600μ/l for Lambaréné; >5000μ/l for Tamale; >8000μ/l for Navrongo.
bAnemia: PCV<25% for Ifakara, Manhiça, and Kumasi; Hb<8g/dl for Kumasi, Lambaréné, and Tamale.
cCombined estimates are basedon random-effects meta-analyses.
dRange: lowest and highest estimated protective efficacy for the sensitivity analyses.
SOURCE: Compiled from data in the Report of the Statistical Working Group (IPTi Consortium, 2007b).
